Iovance Biotherapeutics, Inc.

Ownership Transactions Reported by 16 Insiders

Symbol
IOVA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
825 Industrial Road, 4 Th Floor, San Carlos, CA

Insiders trading volume in the past year

Iovance Biotherapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Wayne P. Rothbaum Director $258M Mar 1, 2024
Merrill A. Mcpeak Director $5.66M Mar 1, 2024
Frederick G. Vogt Interim CEO & General Counsel, Director $1.47M +$42.3K +2.96% Sep 2, 2025
Iain Dukes Director $825K Jun 13, 2025
Daniel Gordon Kirby Chief Commercial Officer $762K +$55.2K +7.81% Jun 5, 2025
Friedrich Graf Chief Medical Officer $553K Sep 2, 2025
Igor Bilinsky Chief Operating Officer $544K Sep 2, 2025
Ryan Maynard Director $488K Jun 13, 2025
Jean-Marc Bellemin Chief Financial Officer $485K Jun 2, 2025
Wendy L. Dixon Director $469K Jun 10, 2022
Wendy L. Yarno Director $413K Jun 13, 2025
Athena Countouriotis Director $413K Jun 13, 2025
Michael Weiser Director $413K Jun 13, 2025
Raj K. Puri Chief Regulatory Officer $369K +$9.74K +2.71% Sep 2, 2025
Matthew W. Rosinack SVP, Finance (Int. PFO & PAO) $160K Jun 30, 2025
Corleen Roche Chief Financial Officer Aug 6, 2025

Recent Insider Transactions by Companies or Individuals for Iovance Biotherapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.